HT2 VARIABILITY IN UTILIZATION OF INNOVATIVE DRUGS IN EUROPE AS A RESULT OF HEALTH TECHNOLOGY ASSESSMENT AND FUNDING PROCEDURES- EXAMPLES OF TRASTUZUMAB AND CETUXIMAB
Abstract
Authors
M Toumi JL Misset O Cristeau L Krukowski S Aballea M Lamure